ArticleMedicine2026
Rising mortality due to coexisting liver cirrhosis and kidney failure in the United States (1999-2023): A nationwide retrospective analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cirrhosis and kidney failure are significant public health concerns, with their coexistence worsening patient outcomes. This study analyzes mortality trends from 1999 to 2023 using Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data to identify high-risk populations and inform public health strategies. Trends in liver cirrhosis and kidney failure mortality were analyzed using a retrospective analysis of death certificates from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. Crude and age-adjusted mortality rates (AAMR) per 1,00,000 people and annual percent change in AAMR with 95% confidence interval were obtained and measured across different demographic and geographic subgroups. Liver cirrhosis and kidney failure registered with total 1,36,947 deaths. The AAMR got doubled from 3.6 in 1999 to 6.3 in 2023. No significant variances were appeared from 1999 to 2018 after which a great surge was seen in AAMR till 2023 (annual percent change: 9.63). AAMR remained higher in males as compared to females during the whole study (overall AAMR: Males 5.6 vs Females 3.2) and peaked in non-Hispanic American Indians or Alaska Natives (7.5) among race/ethnicity. The highest crude mortality rate of 8.0 was noted in population aged 75 to 84 years. The overall AAMR of 4.1 remained similar in both metropolitan and nonmetropolitan areas and the South region had the top AAMR of 4.8 considering geographics. Proper resource distribution and more focused approaches are required to tackle the rising shift in mortality rates among different geographics and demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.